Investment Summary

Malin Invests In Artizan Biosciences

On February 6, 2017, Malin invested in life science company Artizan Biosciences

Investment Highlights
  • This is Malin’s 6th transaction in the Life Science sector.
  • This is Malin’s 3rd transaction in the United States.
  • This is Malin’s 1st transaction in North Carolina.

Investment Summary
Date 2017-02-06
Target Artizan Biosciences
Sector Life Science
Investor(s) Malin
Deal Type Stake Purchase

Target

Artizan Biosciences

Durham, North Carolina, United States
Artizan Biosciences, Inc. is a biotechnology companyfocused on drug discovery and development for diseases involving the human intestinal microbiota. Artizan has developed a proprietary platform for distinguishing pathogenic bacteria from the remainder of the intestinal microbiota and has a therapeutic strategy to target these bacteria as treatment for inflammatory bowel diseases (IBD).

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Malin

Dublin, Ireland
Category Company
Founded 2014
Sector Life Science
Employees255
Revenue 41M EUR (2020)
DESCRIPTION

Malin is a globally operating life sciences company. Malin was founded in 2014 and is based in Dublin, Ireland.

DEAL STATS #
Overall 8 of 8
Sector (Life Science) 6 of 6
Type (Stake Purchase) 4 of 4
State (North Carolina) 1 of 1
Country (United States) 3 of 3
Year (2017) 3 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-01-16 Wren Therapeutics

Cambridge, United Kingdom

Wren Therapeutics Ltd. is a biopharmaceutical company focused on drug discovery and development for protein misfolding diseases, which include Alzheimer's and Parkinson's diseases, type-2 diabetes, and many rare forms of amyloidosis.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-08-09 Melinta Therapeutics

New Haven, Connecticut, United States

Melinta Therapeutics is a molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics.

Sell -
Mergr

Product

Company

Legal